MedTrace Logo

SEMA4C as a Relapse Biomarker in Breast Cancer

NCT03663153 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 4200

Last updated 2021-10-07

No results posted yet for this study

Summary

Breast cancer remains the most common cancer in women worldwide. Semaphorin4C (SEMA4C) has previously been identified as a highly expressed protein by breast cancer-associated lymphatic endothelial cells (LECs). The objective of this study is to investigate SEMA4C's potential role as an early relapse biomarker in breast cancer.

Conditions

Interventions

OTHER

SEMA4C high value follow-up group

Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.

OTHER

SEMA4C low value follow-up group

Serum samples will be collected every 3 months for the first year after surgery and then every 6 months to first progression defined as death or recurrence of the breast cancer or until 5 years since last patient in, whichever occurs first. Imaging examination and biopsy or surgery if necessary are recommended for patients with elevated SEMA4C. Serum SEMA4C levels will be tested in single center in order to decrease bias and be measured using a double antibody sandwich ELISA method using in-house SEMA4C detection kits.

Sponsors & Collaborators

  • Hubei Cancer Hospital

    collaborator OTHER

  • Qilu Hospital of Shandong University

    collaborator OTHER

  • Wuhan Central Hospital

    collaborator OTHER

  • Xiangyang Central Hospital

    collaborator OTHER

  • The First People's Hospital of Jingzhou

    collaborator OTHER

  • The First Affiliated Hospital with Nanjing Medical University

    collaborator OTHER

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Qinglei Gao, MD, PhD · Tongji Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-09-01
Primary Completion
2023-08-01
Completion
2026-08-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03663153 on ClinicalTrials.gov